WELCOME

Help Advance Research for Major Depressive Disorder

About The Study

This Phase 2, double-blind, placebo-controlled clinical trial evaluates the safety and effectiveness of an investigational drug for adults currently experiencing a major depressive episode. The study seeks to learn more about a potential new approach to the treatment of MDD.

Quick Facts

Austin Area

Conducted at Community Clinical Research in Austin, TX.

6-7 Visits

Participation includes clinic visits for health assessments and procedures.

13-Week Study

FIncludes screening, 6 weeks of treatment, and a 4-week follow-up.

Oral Medication

Participants will receive oral capsules of the investigational drug or placebo.

Who Can Participate?
  • Are between the ages of 18 and 65.
  • Have a diagnosis of Major Depressive Disorder (MDD).
  • Are in a depressive episode lasting between 4 weeks and 6 months.
  • Have a BMI between 18.0 and 35.0.
  • Are in general good health and meet all other clinical criteria.

What to Expect:

Clinical interviews and mental health questionnaires.
Routine medical tests including ECGs and blood work.
Physical and neurological examinations.
Monitoring by a specialized research team throughout the study.
Participants who qualify will receive compensation up to $1275 for participation

Click below to see if you qualify

see if you qualify
FAQ

We’ve pulled together some basics to help you

Where does the study take place?

All study visits are conducted at Community Clinical Research in Austin, TX

How long is the study?

The study consists of 6-7 visits over a 13-week study.

Will I receive the study drug?

Participants may receive either the oral investigation drug or a placebo.

Will I be compensated?

Participants can earn up to $1275 for participating in this study. All research study-related visits, tests, and investigational medication will be provided at no cost.